OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).
OBM Neurobiology publishes research articles, technical reports and invited topical reviews. Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Archiving: full-text archived in CLOCKSS.
Publication Speed (median values for papers published in 2022): Submission to First Decision: 6 weeks; Submission to Acceptance: 14 weeks; Acceptance to Publication: 8 days (1-2 days of FREE language polishing included)
Diagnosis, Prognosis, and Treatment of Traumatic Brain Injury
Submission Deadline: December 31, 2023 (Open) Submit Now
Brandon Lucke-Wold, MD, PhD
Department of Neurosurgery, University of Florida, United States
Research interests: traumatic brain injury, neurosurgical simulation, and stroke
Michael J Diaz, MS-1
University of Florida College of Medicine, United States
Research interests: brain injury; neurologic outcomes
About This Topic
Traumatic brain injury (TBI) continues to represent a primary cause of death and disability among emergency department patients in the United States. Diagnosis of TBI commonly incorporates the Glasgow Coma Scale, a history of present illness, and computerized tomography scanning. Mild TBI (mTBI) typically presents as altered mental status with or without loss of consciousness, which potentiates secondary brain injury as many individuals who sustain an initial mTBI do not seek medical attention. Firstline treatment of moderate to severe TBI (msTBI) includes any combination of hematoma removal, surgical relief of intracranial pressure, and administration of neuroprotective medications to avoid additional brain damage by way of hypoxia and/or seizure. However, the msTBI recovery timeline remains long and a significant number fail to fully recover. Here we highlight emerging technologies and important findings in the context of their diagnostic utility, prognostic value, and clinical efficacy for TBI patients. Potential topics include measured outcomes of surgical options for open TBI; population-based analysis of msTBI patient and hospital factors; rehabilitation and combination therapies for acquired deficits; targeted areas of improvement for head trauma care; and identification of novel mTBI biomarkers.
traumatic brain injury; neuroimaging; neuroprotection; penetrating brain injury; closed head trauma; neurologic deficit; concussion; morbidity; diagnostic utility; msTBI
Received: 07 October 2022; Published: 06 March 2023; doi: 10.21926/obm.neurobiol.2301161
Traumatic brain injury (TBI) is a significant source of brain deficit and death among neurosurgical patients, with limited prospects for functional recovery in the cases of moderate-to-severe injury. Until now, the relevant body of literature on TBI intervention has focused on first-line, invasive treatment options (namely craniect [...]
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.